Moretz C, Byfield SD, Hatchell KE, et al. Comparison of germline genetic testing before and after a medical policy covering universal testing among patients with colorectal cancer. *JAMA Netw Open*. 2022;5(10):e2238167. doi:10.1001/jamanetworkopen.2022.38167

**eTable 1.** Genes Included in Invitae’s Multi-cancer Gene Panel  
**eTable 2.** Enrollees Diagnosed with Colorectal Cancer Who Received Germline Genetic Testing 2017–2020 by Policy Type and Age  
**eFigure.** Uptake of Germline Genetic Testing for 2017-2020 by Policy Type and Age  
**eReferences**

This supplementary material has been provided by the authors to give readers additional information about their work.
## eTable 1. Genes Included in Invitae’s Multi-cancer Gene Panel

| High Penetrance (relative risk >4)                                                                 | Moderate Penetrance (relative risk 2–4)                                                                 |
|---------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------|
| ALK, AXIN2, BAP1, BMPR1A, BRCA1, BRCA2, CDH1, CDK4, CDKN1C, CDKN2A, DICER1, EPCAM, FH (biallelic), FLCN, GATA2, HRAS, MEN1, MET, MLH1, MSH2, MSH6, MUTYH (biallelic), NF2, PALB2, PHOX2B, PMS2, PTCH1, PTEN, RB1, RET, RUNX1, SDHA, SDHB, SDHD, SDHC, SMAD4, SMARCA4, SMARCB1, SMARCE1, STK11, SUFU, TERC, TERT, TP53, TSC1, TSC2, VHL | ATM, BLM (biallelic), BRIP1, CASR, CDC73, CDKN1B, CEBPA, CHEK2, GREM1, HOXB13, MAX, MITF, NF1, POLD1, POLE, POT1, PRKAR1A, RAD51C, RAD51D, RECQL4 (biallelic), SDHAF2, TMEM127, WT1                                                                 |
| Low Penetrance (relative risk >2)                                                                   | Recessive Conditions                                                                                   |
| APC (I1307K), BARD1, EGFR, KIT, MUTYH (monoallelic), PDGFRA                                          | BLM (monoallelic), DIS3L2, FH, MSH3, NTHL1, RECQL4, WRN                                                                 |
| No Increased Cancer Risk                                                                            | X-linked Conditions                                                                                   |
| NBN, RAD50                                                                                          | GPC3                                                                                                    |

© 2022 Moretz C et al. JAMA Network Open.
Proportion of patients who underwent germline genetic testing was examined according to policy type and by age, including commercially insured enrollees <65 years, commercially insured enrollees ≥65 years, and Medicare Advantage enrollees. Asterisks indicate values masked to comply with data use policy.
eTable 2. Enrollees Diagnosed with Colorectal Cancer Who Received Germline Genetic Testing 2017–2020 by Policy Type and Age

| Policy Type                     | No. Patients | No. Patients with GGT (%) | P value, overall (P < .05) | P value, per year (P < .0125) |
|---------------------------------|--------------|----------------------------|---------------------------|-------------------------------|
| All Policy Types                |              |                            |                           |                               |
| 2017                            | 2156         | 239 (11.1)                 |                           |                               |
| 2018                            | 2371         | 232 (9.8)                  |                           |                               |
| 2019                            | 2504         | 287 (11.5)                 |                           |                               |
| 2020                            | 2035         | 275 (13.5)                 |                           |                               |
| Commercial                      |              |                            |                           |                               |
| 2017                            | 1283         | 188 (14.7)                 |                           |                               |
| 2018                            | 1291         | 162 (12.5)                 |                           |                               |
| 2019                            | 1395         | 199 (14.3)                 |                           |                               |
| 2020                            | 1134         | 201 (17.7)                 |                           |                               |
| Commercial <65 years            |              |                            |                           |                               |
| 2017                            | 991          | 175 (17.7)                 |                           |                               |
| 2018                            | 993          | 100 (10)\(^b\)            |                           |                               |
| 2019                            | 1142         | 183 (16.0)                 |                           |                               |
| 2020                            | 927          | 186 (21.1)                 |                           |                               |
| Commercial ≥ 65 years           |              |                            |                           |                               |
| 2017                            | 292          | 13 (4.5)                   |                           |                               |
| 2018                            | 298          | <11 (<4)\(^b\)            |                           |                               |
| 2019                            | 253          | 16 (6.3)                   |                           |                               |
| 2020                            | 207          | 15 (7.2)                   |                           |                               |
| Medicare Advantage |   |   | 0.136 | 0.107 |
|-------------------|---|---|-------|-------|
| 2017              | 873| 51 (5.8) |       |       |
| 2018              | 1080| 70 (6.5) | 0.359 |       |
| 2019              | 1109| 88 (7.9) | 0.253 |       |
| 2020              | 901 | 74 (8.2) | 0.178 |       |

αAlpha value was adjusted using Bonferroni correction to account for multiple comparisons
βValues are masked to comply with data use policy

eReferences

1. Kurian AW, Hare EE, Mills MA, et al. Clinical evaluation of a multiple-gene sequencing panel for hereditary cancer risk assessment. *J Clin Oncol*. 2014;32(19):2001-2009.

2. Samadder NJ, Riegert-Johnson D, Boardman L, et al. Comparison of universal genetic testing vs guideline-directed targeted testing for patients with hereditary cancer syndrome. *JAMA Oncol*. 2021;7(2):230-237.

3. Nykamp K, Anderson M, Powers M, et al. Sherloc: a comprehensive refinement of the ACMG–AMP variant classification criteria. *Genet Med*. 2017;19(10):1105-1117.